Fagron NV
OTC:ARSUF
Fagron NV
OTC:ARSUF
Price:
27
USD
Market Closed
Market Cap:
$2B
Relative Value
The Relative Value of one
ARSUF
stock under the Base Case scenario is
28.58
USD.
Compared to the current market price of 27 USD,
Fagron NV
is
Undervalued by 6%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ARSUF
Relative Value
Base Case
28.58
USD
Undervaluation 6%
Multiples Across Competitors
ARSUF Competitors Multiples
Fagron NV Competitors
Fagron NV Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| BE |
|
Fagron NV
OTC:ARSUF
|
1.6B USD | 1.8 | 18.8 | 11.3 | 12.9 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
116B USD | 0.3 | 26.7 | 18.8 | 21.1 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
68.4B USD | 0.2 | 41.8 | 14.7 | 18.6 | |
| US |
|
Cencora Inc
NYSE:COR
|
67.3B USD | 0.2 | 41.5 | 14.6 | 18.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
51.4B USD | 0.2 | 30.9 | 14.9 | 19.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
30.5B AUD | 2.7 | 33.6 | 25 | 25 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
64.3B CNY | 0.2 | 11.4 | 15.3 | 15.3 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
62.2B CNY | 1.4 | 16.8 | 13 | 13 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 0.7 | 21.7 | 10.5 | 14.8 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
67.2B HKD | 0.1 | 8.7 | 1.6 | 2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 5.9 | 89.6 | 59.9 | 61.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
